. 2019 Jul 2;10(8):1187–1192. doi: 10.1021/acsmedchemlett.9b00221

Table 1. List of Current FDA-Approved Immunotherapeutics That Block the PD-1/PD-L1 Interaction¹³⁻¹⁷.

name	company	target	FDA approval year
nivolumab	Bristol-Myers Squibb	PD-1	2014
pembrolizumab	Merck	PD-1	2014
atezolizumab	Genentech/Roche	PD-L1	2016
avelumab	Merck	PD-L1	2017
durvalumab	AstraZeneca	PD-L1	2017
cemiplimab	Regeneron/Sanofi	PD-1	2018

Table 1. List of Current FDA-Approved Immunotherapeutics That Block the PD-1/PD-L1 Interaction13−17.